JPMorgan raised the firm’s price target on Alnylam (ALNY) to $338 from $330 and keeps an Overweight rating on the shares. The firm updated the company’s model to reflect higher Amvuttra estimates.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALNY:
- Cautious Outlook on Alnylam Pharma: Hold Rating Amid Incremental EU Approval and Promising US Sales Projections
- Alnylam receives European Commission approval of AMVUTTRA
- Alnylam Pharma’s Strong Execution and Innovation in ATTR-CM Space Drives Positive Outlook
- Promising Market Outlook and Strong Product Pipeline Drive Buy Rating for Alnylam Pharma
- Positive Buy Rating for Alnylam Pharma Driven by Promising Clinical Data and Strategic Advancements